Venous Thromboembolism Prophylaxis in Hospitalized Medical Patients
Pharmacologic VTE prophylaxis is recommended for most hospitalized medical patients who have additional risk factors for thrombosis [1][2].
Absolute contraindications include active major bleeding, a bleeding diathesis, or a platelet count < 50 × 10⁹/L [1][2].
Indications for Pharmacologic Prophylaxis
- Hospitalized medical patients with reduced mobility plus any of the following: age ≥ 40 yr, active cancer, prior VTE, known thrombophilia, obesity (BMI ≥ 30 kg/m²), or acute inflammatory disease [1][2].
- Patients admitted for acute medical illnesses (e.g., heart failure, respiratory failure, infectious disease) when the anticipated length of stay exceeds 2 days and no absolute bleeding risk is present [1][2].
Absolute Contraindications
- Overt active bleeding or high‑risk bleeding lesion.
- Platelet count < 50 × 10⁹/L.
- Recent (≤ 48 h) intracranial or spinal surgery or trauma.
- Severe coagulopathy (INR > 1.5 unrelated to oral anticoagulation).
Preferred Pharmacologic Agents and Dosing
| Agent | Recommended Dose | Renal Function Consideration |
|---|---|---|
| Low‑molecular‑weight heparin (enoxaparin) | 40 mg subcutaneously once daily | Use 30 mg daily if CrCl < 30 mL/min |
| Unfractionated heparin | 5,000 U subcutaneously every 8 h (or 12 h) | No dose adjustment required |
| Fondaparinux | 2.5 mg subcutaneously once daily | Use 1.5 mg daily if CrCl < 50 mL/min |
Enoxaparin is preferred in patients with normal renal function due to ease of administration and lower monitoring burden [3][2].
Unfractionated heparin is preferred when rapid reversibility is desired or in severe renal impairment.
Fondaparinux is an alternative for patients with heparin‑induced thrombocytopenia risk.
Implementation and Monitoring
- Initiate prophylaxis within 24 h of admission for eligible patients.
- Re‑assess bleeding risk daily; discontinue prophylaxis if an absolute contraindication develops.
- Continue pharmacologic prophylaxis until the patient is fully ambulatory or discharged, whichever occurs first.
These recommendations reflect current CHEST and American Society of Hematology guidance for VTE prophylaxis in medical inpatients.